The dynamics of HER2 status in esophageal adenocarcinoma

Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Creemers, Aafke, Ebbing, Eva A., Hooijer, Gerrit K.J., Stap, Lisanne, Jibodh-Mulder, Rajni A., Gisbertz, Susanne S., van Berge Henegouwen, Mark I., van Montfoort, Maurits L., Hulshof, Maarten C.C.M., Krishnadath, Kausilia K., van Oijen, Martijn G.H., Bijlsma, Maarten F., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003553/
https://www.ncbi.nlm.nih.gov/pubmed/29928485
http://dx.doi.org/10.18632/oncotarget.25507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003553/
https://www.ncbi.nlm.nih.gov/pubmed/29928485
http://dx.doi.org/10.18632/oncotarget.25507

Ejemplares similares